Intravenous kalipsol anesthesia in emergency otorhinolaryngology

This paper discusses the application of intravenous Kalipsol anesthesia in combination with Seduxen (Relanium) in 22 patients who underwent antro-mastoidectomy (expanded) and fronto-ethmoidectomy. No complications related to the method of anesthesia were identified. It is concluded that the use of Kalipsol anesthesia in urgent ENT operations provides better surgical intervention. This method ensures adequate analgesia during operation.     

Calcium metabolism in various forms of hypertrophy of the "hypertensive" heart]

To study the changes occurred in integral calcium metabolic parameters in evolving "hypertensive" heart, a total of 100 patients with Stage I-II (WHO Classification) were examined. Myocardial structure and function were echocardiographically examined. Plasma concentrations of ionized calcium were measured by direct potentiometry. Plasma levels of calcitonin and parathyroid hormone were measured by radioimmunoassay. As the "hypertensive" heart progressed, the ionization of serum calcium was found to enhance along with an increase in calcitoninemia. In early formation of the "hypertensive" heart, parathyroid hormone remained unchanged, but became elevated only in severe left ventricular hypertrophy. The findings may explain the features of the clinical aspects of variant left ventricular hypertrophies in the "hypertensive" heart.     

一叶萩的化学成分

目的：对一叶萩枝叶的化学成分进行研究。方法：应用各种色谱技术从一叶萩总碱部位中分离化合物，根据理化常数和波谱（NMR及MS等）分析方法对化合物的结构进行鉴定。结果：自一叶萩枝叶的总碱部位中分离得到11个化合物。分别鉴定为：（-）-15β-ethoxy-14，15-dihvdroviroallosecurinine（1），一叶萩碱（securinine，2），二氢一叶萩碱（14，15-dihydrosecurinine，3），4-epiph），llanthine（4），securitinine（5），右旋别一叶萩碱（viroallosecurinine，6），一叶萩醇A（securinol A，7），secu’amamineA（8），ent-phyllanthidine（9），（＋）-aquilegiohde（10）和（＋）-menisdaurilide（11）。结论：1为新化合物，4，8，10和11为首次从一叶萩中分离得到。     

Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care

OBJECTIVES: To evaluate the role of intraperitoneal (IP) chemotherapy as part of primary treatment in patients with advanced ovarian cancer and to develop standards of care within the context of current clinical practice. METHODS: A multidisciplinary expert panel, convened to develop standards on the use of IP chemotherapy, searched the MEDLINE, EMBASE, and Cochrane Library databases up to December 2006 for randomized trials or published standards on the efficacy and/or delivery of IP chemotherapy. RESULTS: Eight randomized trials comparing IP chemotherapy versus intravenous (IV) chemotherapy were identified. Three trials reported statistically significant improvements in median survival of 8.0, 11.0, and 15.9 months with cisplatin-based IP chemotherapy. In one trial, the 15.9-month improvement in median overall survival (RR=0.75, 95% CI=0.58-0.97) represented a 25% reduction in the risk of death with IP chemotherapy. Severe adverse events and catheter-related complications were often dose limiting with IP chemotherapy. Using a consensus-based approach with a nationally representative panel, multidisciplinary care standards were developed to review medical and surgical criteria, the practice setting, volume requirements, and the institutional criteria required to safely deliver IP chemotherapy. CONCLUSION: The survival benefits with cisplatin-based IP chemotherapy may represent a significant improvement in the outlook for select patients with advanced ovarian cancer. The delivery of IP chemotherapy is more challenging than the IV route; however, severe adverse events and catheter-related complications may be offset through research defining the optimum treatment regimen, and the standardization of care. System-wide standards for the delivery of IP chemotherapy in Canada for patients with optimally debulked stage III ovarian cancer are offered.     

Hydrodynamic bench rigs for testing assisted circulation apparatus and the artificial heart

Biomedical Engineering -     

Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G- CSF-mediated activation of signaling complexes of the p21ras route

Granulocyte colony-stimulating factor (G-CSF) induces rapid phosphorylation of JAK kinases as well as activation of the p21ras route through interaction with its specific receptor (G-CSF-R). The cytoplasmic membrane-proximal region of G-CSF-R (amino acids 631 to 684) is necessary for proliferation induction and activation of JAK2. In contrast, activation of Shc and Syp, signaling molecules implicated in the p21ras signaling route, depends on the phosphorylation of tyrosine residues located in the membrane-distal region (amino acids 685 to 813) of G-CSF-R. We investigated whether G-CSF-induced activation of signaling complexes of the p21ras route depends on the function of the membrane-proximal cytoplasmic region of G-CSF-R. A G- CSF-R mutant was constructed in which tryptophan 650 was replaced by arginine and expressed in BAF3 cells (BAF/W650R). In contrast to BAF3 cell transfectants expressing wild-type G-CSF-R, BAF/W650-R cells did not proliferate and did not show activation of JAK2, STAT1, or STAT3 in response to G-CSF. Immunoprecipitations with anti-Shc and anti-Grb2 antisera showed that mutant W650R also failed to activate Syp and Shc. These data indicate that the membrane-proximal cytoplasmic domain of G- CSF-R is not only crucial for proliferative signaling and activation of JAK2 and STATs, but is also required for activation of the p21ras route, which occurs via the membrane-distal region of G-CSF-R.